Telaprevir or boceprevir based therapy for chronic hepatitis C infection: Development of resistance-associated variants in treatment failure

Antiviral Research

Volumn 105, Issue 1, 2014, Pages 112-117

  Macartney, Malcolm J ^a   Irish, Dianne ^a   Bridge, Simon H ^a   Garcia Diaz, Ana ^a   Booth, Clare L ^a   McCormick, Adele L ^a   Labbett, Wendy ^a   Smith, Colette ^a   Velazquez, Carmen ^a   Tanwar, Sudeep ^b   Trembling, Paul ^b   Jacobs, Michael ^a   Dusheiko, Geoff ^a   Rosenberg, William ^a,b   Haque, Tanzina ^a  

^a ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Drug resistance; HCV; Protease inhibitors; Telaprevir

Indexed keywords

BOCEPREVIR; HEPATITIS B SURFACE ANTIGEN; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PROTEINASE; TELAPREVIR; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; NS3 PROTEIN, HEPATITIS C VIRUS; OLIGOPEPTIDE; PROLINE; RIBAVIRIN; VIRUS PROTEIN; AMINO ACID DERIVATIVE; INTERLEUKIN 28B; PEGINTERFERON;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; COMPASSIONATE USE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUTROPENIA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REBOUND; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; WEIGHT REDUCTION; AMINO ACID SUBSTITUTION; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; BLOOD; DRUG COMBINATION; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MISSENSE MUTATION; PROCEDURES; TREATMENT FAILURE; CLINICAL TRIAL; COHORT ANALYSIS; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; REDUCTION; RESISTANCE ASSOCIATED VARIANT; TREATMENT OUTCOME; VIRUS RESISTANCE;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MUTATION, MISSENSE; OLIGOPEPTIDES; PROLINE; RIBAVIRIN; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84897372446     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.02.019     Document Type: Article

References (29)

1. N.H. Afdhal, J.G. McHutchison, S. Zeuzem, A. Mangia, J.-M. Pawlotsky, J.S. Murray, K.V. Shianna, Y. Tanaka, D.L. Thomas, D.R. Booth, D.B. Goldstein, and Pharmacogenetics and Hepatitis C Meeting Participants Hepatitis C pharmacogenetics: state of the art in 2010 Hepatology 53 2011 336 345
2. B.R. Bacon, S.C. Gordon, E. Lawitz, P. Marcellin, J.M. Vierling, S. Zeuzem, F. Poordad, Z.D. Goodman, H.L. Sings, N. Boparai, M. Burroughs, C.A. Brass, J.K. Albrecht, R. Esteban, and HCV RESPOND-2 Investigators Boceprevir for previously treated chronic HCV genotype 1 infection N. Eng. J. Med. 364 2011 1207 1217
3. P. Bedossa, and T. Poynard An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group Hepatology 24 1996 289 293 (Pubitemid 26260021)
4. European Association for the Study of the Liver EASL clinical practice guidelines: management of hepatitis C virus infection J. Hepatol. 55 2011 245 264
5. N. Forestier, H.W. Reesink, C.J. Weegink, L. McNair, T.L. Kieffer, H.-M. Chu, S. Purdy, P.L.M. Jansen, and S. Zeuzem Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C Hepatology 46 2007 640 648 (Pubitemid 47436108)
6. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, F.L. Goncales, D.H. Aussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, A. Lin, J. Hoffman, and J. Yu Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection N. Engl. J. Med. 347 2002 975 982
7. D. Ge, J. Fellay, A.J. Thompson, J.S. Simon, K.V. Shianna, T.J. Urban, E.L. Heinzen, P. Qiu, A.H. Bertelsen, A.J. Muir, M. Sulkowski, J.G. McHutchison, and D.B. Goldstein Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
8. K. Ishak, A. Baptista, L. Bianchi, F. Callea, J. De Groote, F. Gudat, H. Denk, V. Desmet, G. Korb, R.N.M. Macsween, M.J. Phillips, B.G. Portmann, H. Poulsen, P.J. Scheuer, M. Schmid, and H. Thaler Histological grading and staging of chronic hepatitis J. Hepatol. 22 1995 696 699
9. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Bisceglie, K.R. Reddy, N.H. Bzowej, P. Marcellin, A.J. Muir, P. Ferenci, R. Flisiak, J. George, M. Rizzetto, D. Shouval, R. Sola, R.A. Terg, E.M. Yoshida, N. Adda, L. Bengtsson, A.J. Sankoh, T.L. Kieffer, S. George, R.S. Kauffman, S. Zeuzem, and ADVANCE Study Team Telaprevir for previously untreated chronic hepatitis C virus infection N. Eng. J. Med. 364 2011 2405 2416
10. T.L. Kieffer, C. Sarrazin, J.S. Miller, M.W. Welker, N. Forestier, H.W. Reesink, A.D. Kwong, and S. Zeuzem Telaprevir and pegylated interferon-alfa-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients Hepatology 46 2007 631 639 (Pubitemid 47436107)
11. O. Lenz, J. de Bruijne, L. Vjigen, T. Verbinnen, C. Weegink, H. Van Marck, I. Vandenbroucke, M. Peters, K. Simmen, G. Fanning, R. Verloes, G. Picchio, and H. Reesink Efficacy of re-treatment with TMC435 as combination treatment in hepatitis C virus-infected patients following TMC435 mono-therapy Gastroenterology 143 2012 1176 1178
12. H. Li, M.B. Stoddard, S. Wang, L.M. Blair, E.E. Giorgi, E.H. Parrish, G.H. Learn, P. Hraber, P.A. Goepfert, M.S. Saag, T.N. Denny, B.F. Haynes, B.H. Hahn, R.M. Ribiero, A.S. Perelson, B.T. Korber, T. Bhattacharya, and G.M. Shaw Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing PLoS Pathog. 8 2012 e1002880
13. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, M. Reindollar, Z.D. Goodman, K. Koury, M.-H. Ling, J.K. Albrecht, and International Hepatitis Interventional Therapy Group Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965 (Pubitemid 32913521)
14. J.G. McHutchison, E.J. Lawitz, M.L. Shiffman, A.J. Muir, G.W. Galler, J. McCone, L.M. Nyberg, W.M. Lee, R.H. Ghalib, E.R. Schiff, J.S. Galati, B.R. Bacon, M.N. Davis, P. Mukhopadhyay, K. Koury, S. Noviello, L.D. Pedicone, C.A. Brass, K.K. Albrecht, M.S. Sulkowski, and IDEAL Study Team Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection N. Eng. J. Med. 361 2009 580 593
15. M.A. Montes-Cano, J.R. Garcia-Lozano, C. Abad-Molina, M. Romero-Gomez, N. Barroso, J. Aguilar-Reina, A. Nunez-Rolda, and M.F. Gonzalez-Escrabino Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes Hepatology 52 2010 33 37
16. National Institute for Health and Clinical Excellence, 2012. Telaprevir for the treatment of genotype 1 chronic hepatitis C, http://www.nice.org.uk/ nicemedia/live/13717/58912/58912.pdf.
17. J. Parkes, I.N. Guha, P. Roderick, R. Cross, M.M. Manos, W. Irving, A. Zaitoun, M. Wheatley, S. Ryder, and W. Rosenberg Enhanced liver fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C J. Viral Hepat. 18 2011 23 31
18. J.M. Pawlotsky Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus Hepatology 53 2011 1742 1751
19. F. Poordad, K.R. Reddy, and P. Martin Rapid virologic response: a new milestone in the management of chronic hepatitis C Clin. Infect. Dis. 46 2008 78 84 (Pubitemid 351263563)
20. F. Poordad, J. McCone, B.R. Bacon, S. Bruno, M.P. Manns, M.S. Sulkowski, I.M. Jacobson, K.R. Reddy, Z.D. Goodman, N. Bopariai, M.J. DiNubile, V. Sniuliene, C.A. Brass, J.K. Albrecht, J.-P. Bronowcki, and SPRINT-2 Investigators Boceprevir for untreated chronic HCV genotype 1 infection N. Eng. J. Med. 364 2011 1195 1206
21. L. Rong, H. Dahari, R.M. Ribiero, and A.S. Perelson Rapid emergence of protease inhibitor resistance in hepatitis C virus Sci. Transl. Med. 2 2010 30ra32
22. Sarrazin, C.; Reesink, H.W.; Zeuzem, S.; Dierynck, I.; Luo, D.; Witek, J.; Picchio, G.; De Meyer, S.; 2013. Treatment with telaprevir/peg-IFN/RBV after 14-day telaprevir exposure in phase I studies: results from the phase IIIB C219 rollover study [abstract 898]. In: Programme and Abstracts of the 48th Annual Meeting of the European Association for the Study of the Liver (Amsterdam). European Association for the Study of the Liver 58, S369-S670.
23. V. Suppiah, M. Moldovan, G. Ahlenstiel, T. Berg, M. Weltman, M.L. Abate, M. Bassendine, U. Spengler, G.J. Dore, E. Powell, S. Riordan, D. Sheridan, A. Smedile, V. Fragomeli, T. Mullet, M. Bahlo, G.J. Stewart, D.R. Booth, J. George, and Hepatitis C Study IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat. Genet. 41 2009 1100 1104
24. S. Susser, C. Welsch, Y. Wang, M. Zettler, F.S. Domingues, U. Karey, E. Hughes, R. Ralston, X. Tong, E. Herrmenn, S. Zeuzem, and S. Sarrazin Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients Hepatology 50 2009 1709 1718
25. Y. Tanaka, N. Nishida, M. Sugiyama, M. Kurosaki, K. Matsuura, N. Sakamoto, M. Nakagawa, M. Korenaga, K. Hino, S. Hige, Y. Ito, E. Mita, E. Tanaka, S. Mochida, Y. Murawaki, M. Honda, A. Sakai, Y. Hiasa, S. Nishiguchi, A. Koike, I. Sakaida, M. Imamura, K. Ito, K. Yano, N. Masaki, F. Suguachi, N. Izumi, K. Tokunaga, and M. Mizokami Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat. Genet. 41 2009 1105 1109
26. D.L. Thomas, C.L. Thio, M.P. Martin, Y. Qi, D. Ge, C.O. O'hUigin, J. Kidd, S.I. Khakoo, G. Alexander, J.J. Goedert, G.D. Kirk, S.M. Donfield, H.R. Rosen, L.H. Tobler, M.P. Busch, J.G. McHutchison, D.B. Goldstein, and M. Carrington Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 461 2009 798 801
27. C. Welsch, F.S. Domingues, S. Susser, I. Antes, C. Hartmann, G. Mayr, A. Schlicker, C. Sarrazin, M. Albrecht, S. Zeuzem, and T. Lengauer Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus Genome Biol. 9 2008 R16
28. S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago, S. Roberts, R. Focaccia, Z. Younossi, G.R. Foster, A. Horban, P. Ferenci, F. Nevens, B. Mullhaupt, P. Pockros, R. Terg, D. Shouval, B. van Hoek, O. Weiland, R. Van Heeswijk, S. De Meyer, D. Luo, G. Boogaerts, R. Polo, G. Picchio, M. Beumont, and Realize Study Team Telaprevir for retreatment of HCV infection N. Eng. J. Med. 364 2011 2417 2428
29. M. Ziol, A. Handra-Luca, A. Kettaneh, C. Christidis, F. Mal, F. Kazemi, V. de Ledinghen, P. Marxellin, D. Dhumeaux, J.C. Trinchet, and M. Beaugrand Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C Hepatology 41 2005 48 54 (Pubitemid 40066382)